|
|
Protective
effect of coenzyme Q10 on anthracyclines cardiotoxicity: control study in
children with acute lymphoblastic leukemia and non-Hodgkin lymphoma
Iarussi D, Auricchio U, Agretto A, Murano A, Giuliano M,
Casale F, Indolfi P, Iacono A
Medical-Surgery
Institute of Cardiology, 2nd University of Naples, Italy
Two
groups of children with acute lymphoblastic leukemia or non-Hodgkin lymphoma,
treated with anthracyclines (ANT), were studied: group I, consisting of 10
patients, with coenzyme Q10 (CoQ) therapy; group II, consisting of 10 patients
without CoQ therapy.
The ANT cumulative dose was 240 +/- 20.0 mg/m2 in group I and 252.0 +/- 20.1
mg/m2 in group II.
Echocardiographic study was performed at the beginning, at the cumulative dose
of 180 mg/m2 and at the end of therapy with ANT. Percentage left ventricular
fractional shortening (%LVFS) decreased from baseline (40.36 +/- 4.6) to end
value (35.82 +/- 5.02) (P < 0.05) in group I; %LVFS decreased from baseline
(39.89 +/- 4.37) to end value (33.43 +/- 3.46) (P < 0.002) in group II.
Interventricular septum wall thickening decreased only in group II from
baseline (46.10 +/- 10.1) to end therapy (27.00 +/- 18.54) (P < 0.01).
Septum wall motion abnormalities were detected only in 2 patients of group II.
These data demonstrate a protective effect of CoQ on cardiac function during
therapy with ANT.
PMID:
7752832 [PubMed - indexed for MEDLINE]
Source:
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=7752832&dopt=Abstract
|
